Pictor Holdings Secures $7.5 Million to Expand Protein Analysis Platform
The funding will support manufacturing and commercial partnerships for a system that analyzes multiple protein targets in less than two hours.
The funding will support manufacturing and commercial partnerships for a system that analyzes multiple protein targets in less than two hours.
Agilent Technologies has partnered with OpenAI and Boston Consulting Group to accelerate artificial intelligence deployment in lab workflows, aiming to deliver faster scientific insights and advance intelligent instruments, software, and services.
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
The FDA has approved Guardant360 Liquid CDx, a blood-based test that integrates genomic and epigenomic profiling for advanced cancer, offering a broader genomic footprint and faster results.
Read MoreTGen has launched JAYseq, a clinical whole genome sequencing test for multiple myeloma that delivers results in 72 hours, enabling rapid identification of genetic changes and immunotherapy targets, according to the institute.
Read MoreCleveland Diagnostics has received ISO 13485:2016 certification for its IsoPSA Assay, supporting scaled U.S. commercialization following recent FDA approval for prostate cancer risk assessment.
Read MoreDiasorin has received FDA 510(k) clearance for its customizable LIAISON PLEX Gastrointestinal Flex Assay, allowing labs to select from 24 targets to tailor testing based on patient needs and operational priorities.
Read MoreLabcorp has launched MyLabcorp, a mobile app that uses OpenAI models to help patients interpret lab results and track health trends. The company cites growing consumer demand for AI-powered health information and clinical context.
Read MoreCMS has expanded Medicare coverage for Personalis’ NeXT Personal MRD test, now allowing immunotherapy monitoring in late-stage solid tumor patients, supported by recent clinical evidence from Vall d’Hebron Institute of Oncology.
Read MoreBillionToOne has launched Unity Confirm, a non-invasive prenatal test that isolates fetal cells from maternal blood to confirm high-risk screening results, addressing the gap between NIPT and invasive diagnostics.
Read MoreThe FDA has cleared Datar Cancer Genetics’ CellDx-Tissue, a genomic profiling assay that analyzes 517 cancer-associated genes from solid tumor tissue to support clinical decision-making, according to the company.
Read MoreCaris Life Sciences has applied to the New York State Department of Health for authorization of Caris Assure, a blood-based molecular profiling test for cancer using whole exome and transcriptome sequencing of 22,000 genes.
Read MoreAmplified Sciences has launched the PanAMP multicenter study to assess how its PanCystPro assay impacts clinical management decisions for patients with radiographically confirmed pancreatic cystic lesions.
Read MoreLucent Diagnostics and Tempus AI have partnered to integrate blood-based Alzheimer’s biomarker testing into clinical workflows, aiming to expand access and improve detection accuracy for neurologists.
Read MoreRoche has received CE mark approval for its Elecsys pTau217 blood test, designed to aid in Alzheimer’s disease diagnosis by detecting amyloid pathology in patients with cognitive decline.
Read MoreBio-Rad has expanded its TrailBlazer StarBright Dye Label Kits to 32 options, now available in Europe for flow cytometry and fluorescent western blot applications, according to the company.
Read MoreSynergen Health has introduced IGNITE, an AI-driven revenue cycle management platform for laboratories, aiming to streamline billing and reduce claim denials through automated processes and specialized RCM teams, according to the company.
Read MoreAvant Genomics has secured over $3 million in funding to develop its Avant Source platform, which aims to automate liquid biopsy sample preparation and improve cell-free DNA recovery.
Read More